Анализ ассоциаций полиморфизма гена МАОА с агрессивными и враждебными стратегиями в поведении у подростков и молодых людей

The article brings forward the results of the study of the relationship between polymorphisms of the MAOA gene and psychological characteristics such as hostility and types of aggressive behavior. Aggression is considered as any intentional actions aimed at causing harm to another person, group of people or animal. The authors of the article mean by hostility a negative, opposition attitude to theworld; it is predominantly of a cognitive nature and presupposes the presence of negative emotions and behavioral manifestations.This paper describes various psychophysiological predictors of aggressive behavior and examines the results of domestic and foreign research of the relationship between polymorphic variants of the MAOA gene with various psychological characteristics.The authors carried out an interdisciplinary molecular-genetic and psychological study. 285 persons aged 12–19 years took part in it. In order to identify polymorphic variants of the MAOA gene they used the method for the isolation of genomic DNA from buccal epithelial cells. Psychological tools included the questionnaire Bass–Darky which is reckoned one of the most reliable methods for studying aggression. For statistical processing of the results the PSPP 0.8.5 program wasused. The results of the carried out study in the group of adolescents and young people show that the low-activity variant of the monoamine oxidase A (MAOA) gene (LPR) in adolescents and young people is the most signiYcant among the genetic polymorphisms which determine the risk of aggressive and hostile behavior. The data should be taken into account in psycho-preventive activities.В статье представлены результаты исследования, посвященного изучению связи полиморфизмов гена МАОА с такими психологическими особенностями, как враждебность и виды агрессивного поведения. Агрессия рассматривается как любые намеренные действия, которые направлены на причинение ущерба другому человеку, группе людей или животному. Под враждебностью в статье понимается негативное, оппозиционное отношение к окружающему миру преимущественно когнитивного характера, подразумевающее наличие негативных эмоций и поведенческих проявлений. Описаны различные психофизиологические предикторы агрессивного поведения. Рассматриваются результаты отечественных и зарубежных исследований, посвященных изучению связи полиморфных вариантов гена МАОА с различными психологическими особенностями. Проведено междисциплинарное молекулярно-генетическое и психологическоеисследование 285 лиц в возрасте 12–19 лет. В целях определения полиморфных вариантов гена МАОА использовался метод выделения геномной ДНК из клеток буккального эпителия. В качестве психологического инструментария использовался опросник Басса–Дарки, считающийся одной из самых надежных методик исследования агрессии. Статистическую обработку результатов проводили с использованием программы PSPP 0.8.5. В результате проведенного исследования в группе подростков и молодых людей выявлено, что среди генетических полиморфизмов, которые определяют риск агрессивного и враждебного поведения, наибольшую роль играет низкоактивный вариант гена фермента моноаминоксидазы А МАОА (LPR) у лиц подросткового и молодого возрастов. Данные следует учитывать при  проведении  психолого-профилактических мероприятий

Influences of Co-Content on the Physico-Chemical and Catalytic Properties of Perovskite GdCo_xFe_1−xO₃ in CO Hydrogenation

The effect of the substitution of cobalt into the GdFeO3 perovskite structure on the selective hydrogenation of CO was investigated. A series of GdCoxFe1−xO3 (x = 0; 0.2; 0.5; 0.8; 1) samples were synthesized by sol-gel technology and characterized by XRD, BET specific area, DSC, TG, EDX and XPS. The experimental data made it possible to reveal a correlation between the state of iron and cobalt atoms, the fractions of surface and lattice oxygen, and catalytic characteristics. It has been found that varying the composition of GdCoxFe1−xO3 complex oxides leads to a change in the oxygen-metal binding energy in Gd-O-Me, the ratio of metals in various oxidation states, and the amount of surface and lattice oxygen, which affects the adsorption and catalytic characteristics of complex oxides

Insights into the Reactivity of Gd_2−xSr_xFe₂O₇ (x = 0 ÷ 0.4) in CO Radical Hydrogenation

The effect of strontium substitution in the structure of the complex oxide Gd2SrFe2O7 on the production of light olefins by CO hydrogenation was investigated. Perovskite-type oxides Gd2−xSr1+xFe2O7 (x = 0; 0.1; 0.2; 0.3; 0.4) were synthesized by sol–gel technology and characterized by XRD, Mössbauer spectroscopy, BET specific area, acidity testing, and SEM. The experimental data revealed a correlation between the state of iron atoms, acidity, and catalytic performance. It was found that with an increase in the content of Sr2+ in the perovskite phase, the basicity of the surface and the oxygen diffusion rate increased. This contributed to the CO dissociative adsorption, formation of active carbon, and its further interaction with atomic hydrogen

Effect of recombinant zoster vaccine on incidence of Herpes zoster after autologous stem cell transplantation : a randomized clinical trial

IMPORTANCE Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantation zoster. OBJECTIVE To assess the efficacy and adverse event profile of the recombinant zoster vaccine in immunocompromised autologous HSCT recipients. DESIGN, SETTING, AND PARTICIPANTS Phase 3, randomized, observer-blinded study conducted in 167 centers in 28 countries between July 13, 2012, and February 1, 2017, among 1846 patients aged 18 years or older who had undergone recent autologous HSCT. INTERVENTIONS Participants were randomized to receive 2 doses of either recombinant zoster vaccine (n=922) or placebo (n=924) administered into the deltoid muscle; the first dose was given 50 to 70 days after transplantation and the second dose 1 to 2 months thereafter. MAIN OUTCOMES AND MEASURES The primary end point was occurrence of confirmed herpes zoster cases. RESULTS Among 1846 autologous HSCT recipients (mean age, 55 years; 688 [37%] women) who received 1 vaccine or placebo dose, 1735 (94%) received a second dose and 1366 (74%) completed the study. During the 21-month median follow-up, at least 1 herpes zoster episode was confirmed in 49 vaccine and 135 placebo recipients (incidence, 30 and 94 per 1000 person-years, respectively), an incidence rate ratio (IRR) of 0.32 (95% CI, 0.22-0.44; P<.001), equivalent to 68.2% vaccine efficacy. Of 8 secondary end points, 3 showed significant reductions in incidence of postherpetic neuralgia (vaccine, n=1; placebo, n=9; IRR, 0.1; 95% CI, 0.00-0.78; P=.02) and of other prespecified herpes zoster-related complications (vaccine, n=3; placebo, n=13; IRR, 0.22; 95% CI, 0.04-0.81; P=.02) and in duration of severe worst herpes zoster-associated pain (vaccine, 892.0 days; placebo, 6275.0 days; hazard ratio, 0.62; 95% CI, 0.42-0.89; P=.01). Five secondary objectives were descriptive. Injection site reactions were recorded in 86% of vaccine and 10% of placebo recipients, of which pain was the most common, occurring in 84% of vaccine recipients (grade 3: 11%). Unsolicited and serious adverse events, potentially immune-mediated diseases, and underlying disease relapses were similar between groups at all time points. CONCLUSIONS AND RELEVANCE Among adults who had undergone autologous HSCT, a 2-dose course of recombinant zoster vaccine compared with placebo significantly reduced the incidence of herpes zoster over a median follow-up of 21 months. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0161041

Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial

IMPORTANCE Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantation zoster. OBJECTIVE To assess the efficacy and adverse event profile of the recombinant zoster vaccine in immunocompromised autologous HSCT recipients. DESIGN, SETTING, AND PARTICIPANTS Phase 3, randomized, observer-blinded study conducted in 167 centers in 28 countries between July 13, 2012, and February 1, 2017, among 1846 patients aged 18 years or older who had undergone recent autologous HSCT. INTERVENTIONS Participants were randomized to receive 2 doses of either recombinant zoster vaccine (n=922) or placebo (n=924) administered into the deltoid muscle; the first dose was given 50 to 70 days after transplantation and the second dose 1 to 2 months thereafter. MAIN OUTCOMES AND MEASURES The primary end point was occurrence of confirmed herpes zoster cases. RESULTS Among 1846 autologous HSCT recipients (mean age, 55 years; 688 [37%] women) who received 1 vaccine or placebo dose, 1735 (94%) received a second dose and 1366 (74%) completed the study. During the 21-month median follow-up, at least 1 herpes zoster episode was confirmed in 49 vaccine and 135 placebo recipients (incidence, 30 and 94 per 1000 person-years, respectively), an incidence rate ratio (IRR) of 0.32 (95% CI, 0.22-0.44; P&lt;.001), equivalent to 68.2% vaccine efficacy. Of 8 secondary end points, 3 showed significant reductions in incidence of postherpetic neuralgia (vaccine, n=1; placebo, n=9; IRR, 0.1; 95% CI, 0.00-0.78; P=.02) and of other prespecified herpes zoster-related complications (vaccine, n=3; placebo, n=13; IRR, 0.22; 95% CI, 0.04-0.81; P=.02) and in duration of severe worst herpes zoster-associated pain (vaccine, 892.0 days; placebo, 6275.0 days; hazard ratio, 0.62; 95% CI, 0.42-0.89; P=.01). Five secondary objectives were descriptive. Injection site reactions were recorded in 86% of vaccine and 10% of placebo recipients, of which pain was the most common, occurring in 84% of vaccine recipients (grade 3: 11%). Unsolicited and serious adverse events, potentially immune-mediated diseases, and underlying disease relapses were similar between groups at all time points. CONCLUSIONS AND RELEVANCE Among adults who had undergone autologous HSCT, a 2-dose course of recombinant zoster vaccine compared with placebo significantly reduced the incidence of herpes zoster over a median follow-up of 21 months. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0161041

Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial

IMPORTANCE Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantation zoster. OBJECTIVE To assess the efficacy and adverse event profile of the recombinant zoster vaccine in immunocompromised autologous HSCT recipients. DESIGN, SETTING, AND PARTICIPANTS Phase 3, randomized, observer-blinded study conducted in 167 centers in 28 countries between July 13, 2012, and February 1, 2017, among 1846 patients aged 18 years or older who had undergone recent autologous HSCT. INTERVENTIONS Participants were randomized to receive 2 doses of either recombinant zoster vaccine (n=922) or placebo (n=924) administered into the deltoid muscle; the first dose was given 50 to 70 days after transplantation and the second dose 1 to 2 months thereafter. MAIN OUTCOMES AND MEASURES The primary end point was occurrence of confirmed herpes zoster cases. RESULTS Among 1846 autologous HSCT recipients (mean age, 55 years; 688 {[}37\%] women) who received 1 vaccine or placebo dose, 1735 (94\%) received a second dose and 1366 (74\%) completed the study. During the 21-month median follow-up, at least 1 herpes zoster episode was confirmed in 49 vaccine and 135 placebo recipients (incidence, 30 and 94 per 1000 person-years, respectively), an incidence rate ratio (IRR) of 0.32 (95\% CI, 0.22-0.44; P<.001), equivalent to 68.2\% vaccine efficacy. Of 8 secondary end points, 3 showed significant reductions in incidence of postherpetic neuralgia (vaccine, n=1; placebo, n=9; IRR, 0.1; 95\% CI, 0.00-0.78; P=.02) and of other prespecified herpes zoster-related complications (vaccine, n=3; placebo, n=13; IRR, 0.22; 95\% CI, 0.04-0.81; P=.02) and in duration of severe worst herpes zoster-associated pain (vaccine, 892.0 days; placebo, 6275.0 days; hazard ratio, 0.62; 95\% CI, 0.42-0.89; P=.01). Five secondary objectives were descriptive. Injection site reactions were recorded in 86\% of vaccine and 10\% of placebo recipients, of which pain was the most common, occurring in 84\% of vaccine recipients (grade 3: 11\%). Unsolicited and serious adverse events, potentially immune-mediated diseases, and underlying disease relapses were similar between groups at all time points. CONCLUSIONS AND RELEVANCE Among adults who had undergone autologous HSCT, a 2-dose course of recombinant zoster vaccine compared with placebo significantly reduced the incidence of herpes zoster over a median follow-up of 21 months. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0161041